Scientific deep-dive
Cancer Risk in People Without Diabetes
A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.
Most studies of these drugs and cancer are done in people with diabetes, where the comparison drug is itself a marker of how sick someone is. This one was done in obese adults without diabetes, and found 41% lower incidence of obesity-associated cancers.[1] It also has a median follow-up of two years, which is the problem.
What was found
After propensity score matching, GLP-1 users had a significantly lower incidence of obesity-associated cancers, with a hazard ratio of 0.59 (95% CI 0.53 to 0.67). Participants had a mean age of 47.2. An inverse probability of treatment weighting analysis confirmed the finding, and it held across subgroups, with one exception discussed below.[1]
The population is what this study adds. We have written about a study reporting 91% lower breast cancer mortality that evaporated against a fair comparator, because insulin users are sicker than GLP-1 users by definition. Studying people without diabetes removes that specific problem.
Two years is not long enough to answer this
A cancer diagnosed within two years of starting a drug was, in most cases, already there when the drug started.
Solid tumors develop over years to decades. A median follow-up of two years, with an interquartile range of one to two, captures diagnoses rather than causation. The authors describe the result as a short-term incidence finding and call for prospective trials to confirm causality.[1]
This is the same structural limitation we found in the randomized evidence: a systematic review in the Annals of Internal Medicine concluded that any effect of these drugs on obesity-related cancers may be little or none, while noting the included trials were not designed to evaluate cancer outcomes and had short follow-up. That is in the randomized answer.
The subgroup that did not follow the pattern
The association held in every subgroup examined except Black patients.[1] The careful reading of that finding is not a biological one.
We covered the same shape in who responds in the real world, where a real-world cohort found weight-loss outcomes differing by race while 64 randomized trials found none. The explanation there applies here: trials equalize access, continuity and follow-up, and ordinary care does not. A benefit that requires sustained treatment will appear smaller in any group whose treatment is more often interrupted. A benefit measured by diagnosis also depends on who receives screening.
Reading a subgroup difference in an observational cancer study as a difference in how bodies respond, rather than in how care is delivered, would be unsupported by the randomized evidence and would mislocate the problem.
Where this leaves the question
- The direction is consistent across cohorts, drug classes and now a nondiabetic population, which carries some weight.
- The magnitude is not. A 41% reduction is large enough to trigger the rule we set out in when a hazard ratio is too good: in observational data, big effects usually describe who was prescribed the drug.
- The mechanism is plausible. Obesity is an established driver of the thirteen cancer types usually classed as obesity-associated, and these drugs reduce obesity.
- The follow-up cannot support the claim. Two years is too short to answer this question, whatever result it shows.
Nothing here is a reason to take or avoid one of these drugs on cancer grounds, and no GLP-1 is indicated for cancer prevention anywhere.
Frequently Asked Questions
References
- 1.Hsu AH, Ramirez PT, Chang YH, et al. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults Annals of Oncology. 2026. PMID: 42252247.
Compare the sellers
Related research
GLP-1s and Cancer: What the Cohorts Actually Show
One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.
7 min read
GLP-1s in People Being Treated for Cancer
Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.
5 min read
GLP-1s and Cancer: The Randomized Answer
Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.
6 min read
The Group That Lost Least Did Best
A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.
6 min read
Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show
GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.
11 min read
Compounded GLP-1s and the Adverse Event Reports
A FAERS study found more adverse event reports for compounded GLP-1s. Reports are voluntary and there is no denominator, but one finding survives that critique: preparation and prescribing errors were reported more often for compounded products, while dosing errors were reported less often.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →